Ethnic differences in the VKORC1 gene polymorphism and an association with warfarin dosage requirements in cardiovascular surgery patients

Pharmacogenomics

Volumn 8, Issue 7, 2007, Pages 713-719

  Nakai, Kenji ^a   Tsuboi, Jyunichi ^a   Okabayashi, Hitoshi ^a   Fukuhiro, Yoshiaki ^a   Oka, Takanori ^a   Habano, Wataru ^a   Fukushima, Noriko ^a   Nakai, Keiko ^a   Obara, Wataru ^a   Fujioka, Tomoaki ^a   Suwabe, Akira ^a   Gurwitz, David ^b  

^a IWATE MEDICAL UNIVERSITY   (Japan)

^b TEL AVIV UNIVERSITY   (Israel)

Author keywords

Anticoagulation; Athnic groups; Cardiovascular surgery; Coumarins; Drug safety; Personalized medicine; Pharmacogenetics; Pharmacogenomics; VKORC1

Indexed keywords

OXIDOREDUCTASE; PROTEIN VKORC1; UNCLASSIFIED DRUG; VITAMIN K EPOXIDE REDUCTASE COMPLEX 1; WARFARIN;

ADULT; AGED; ANGINA PECTORIS; AORTA STENOSIS; AORTA VALVE REGURGITATION; ARTICLE; CARDIOVASCULAR SURGERY; CAUCASIAN; CONTROLLED STUDY; ETHNIC DIFFERENCE; FEMALE; GENE FREQUENCY; GENOTYPE; HEART INFARCTION; HUMAN; INTRON; ISRAEL; JAPAN; JAPANESE; JEW; MAJOR CLINICAL STUDY; MALE; MITRAL VALVE REGURGITATION; MITRAL VALVE STENOSIS; REAL TIME POLYMERASE CHAIN REACTION; SINGLE NUCLEOTIDE POLYMORPHISM; SURGICAL PATIENT;

ANTICOAGULANTS; ASIAN CONTINENTAL ANCESTRY GROUP; CARDIOVASCULAR DISEASES; CARDIOVASCULAR SURGICAL PROCEDURES; DOSE-RESPONSE RELATIONSHIP, DRUG; ETHNIC GROUPS; GENOTYPE; HUMANS; INTRONS; JAPAN; JEWS; MIXED FUNCTION OXYGENASES; POLYMORPHISM, GENETIC; POLYMORPHISM, SINGLE NUCLEOTIDE; WARFARIN;

EID: 34548060277     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/14622416.8.7.713     Document Type: Article

References (30)

1. Marketos M: The top 200 generic drugs in 2003 (by units). Drug Topics 148, 76-76 (2004).
2. Pirmohamed M, James S. Meekin S et al: Adverse drug reactions as cause of admission to hospital: prospective analysis of 18,820 patients BMJ 329,15-19 (2004).
3. Pirmohamed M: Warfarin: almost 60 years old and still causing problems Br. J. Clin. Pharmacol. 62, 509-511 (2006).
4. Wadelius M, Pirmohamed M: Pharmacogenetics of warfarin: current status and future challenges Pharmacogenomics J. 7(2).99-111 (2007).
5. Evans WE, Johnson JA: Pharmacogenomics the inherited basis for inter individual differences in drug response. Annu. Rev. Genomics Hum. Genet. 2,29-39 (2001).
6. Hermida J, Zarza J, Albercal et al: Differential effects of 2C9*3 and 2C9*2 variants of cytochrome P-450 CYP2C9 on sensitivity to acenocoumarol. Blood 99, 4237-4239(2002).
7. Higashi M K, Veenstra D L, Kondo LM et al: Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy. JAMA 287,1690-1698 (2002).
8. Zao F, Loke C, Rankin SC et al: Novel CYP2C9 genetic variants in Asian subjects and their influence on maintenance warfarin dose. Clin. Pharmacol. Ther. 76, 210-219 (2004).
9. XieH G, Prased HC, Kim RB et al: CYP2C9 allelic variants ethnic distribution and functional significance. Adv. Drug Deliv. Rev. 54, 1257-1270 (2002).
10. Nakai K, H abano W, Nakai K et al.: Ethhic differences in CYP2C9*2 (Arg144Cys) and CYP2C9*3 (IIe359Leu) genotypes in Japanese and Israel populations Life Sci. 78, 107-111 (2005).
11. Rost S, Fregin A, Ivaskevicius V et al.: Mutations in VKORC1 cause warfarin resistance and multiple coagulation factor deficiency type 2. Nature 427, 537-541 (2004).
12. Li T, Chang CY, Jn D Y et al.: Identification of the gene for vitamin K epoxide reductase Nature 427, 541-544 (2004).
13. Rieder M J, Reiner AP, Gage BF et al.: Effect of VKORC1 haplo types on transcriptional regulation and warfarin dose. N. Engl. J, Med. 353,2285-2293 (2005).
14. Li T, Lange LA, Li X et al.: Polymorphisms in the VKORC1 gene are strongly associated with warfarin dosage requirements in patients receiving anticoagulation. J. Med. Genet. 43,740-744 (2006).
15. Obayashi K, Nakamura K, Kawana J et al.: VKORC1 genea variations are the major contributors of variation in warfarin dose in Japanese patients. Clin. Pharmacol. Ther. 80, 169-178 (20O6).
16. Mushiroda T, Ohnishi Y, Saito S et al.: Association of VKORC1 and CYP2C9 polymorphisms with warfarin dose requirements in Japanese patients J Hum. Genet. 51, 249-253 (2006).
17. Takahashi H, Wilkinson GR, Nutescu EA et al.: Different contributions of polymorphisms in VKORC1 and CYP2C9 to intra- and inter-population differenses in maintenance dose of warfarin in Japanese, Caucasians and African-Americans Pharmaco genet. Genomics 16, 101-110 (2DO6).
18. Hirsh J, Fuster V: Guide to anticoagulant therapy. Part 2: Oral anticoagulants (American Heart Association Guideline). Circulation 89, 1469-1480 (1995).
19. Yuan HY, Chen JJ, Lee M T et al.: A novel functional VKORC1 promoter polymorphism is associated with inter-individual and inter-ethnic differences in warfarin sensitivity. Hum Mol. Genet. 14, 1745-1751 (2005).
20. Engen RM, Marsh S, van Booven DJ et al.: Ethnic differences pharmacogenetically relevant genes Curr. Drug Targets 7, 1641-1648 (2006).
21. Lee SC, Ng SS, Oldenburg J et al.: Interethnic variability of warfarin maintenance requirement is explained by VKORC1 genotype in an Asian population. Clin. Pharmacol. Ther. 79, 197-205 (2006).
22. Tham LS, Goh BC, Nafziger A et al.: A warfarin-dosing model in Asians that uses single-nucleo tide polymorphism in vitamin K epoxide reductase complex and cytochrome P450 2C9. Clin. Pharmacol. Ther. 80, 346-355 (2006).
23. Zineh I, Gerhard T, Aquilante CL et al.: Availability of pharmaco genomics-based prescribing information in drug package inserts for currently approved drugs. Pharmaco genomics J. 4, 354-358 (2004).
24. Iqbal O: Pharmaco genomics in anticoagulant drug development. Pharmaco genomics 3, 823-828 (2002).
25. Holbrook AM, Pereira JA, Labiris R et al.: Systematic overview of warfarin and its drug and food interactions Arch. Intern. Med. 165, 1095-1106(2005).
26. Greenblatt DJ, von Moltke LL: Interaction of warfarin with drugs, natural substances, and foods J. Clin. Pharmacol. 45, 127-132 (2005).
27. Hirsh J. Fuster V, Apsell J et al.: American Heart Association/American College of Cardiology Foundation guide to warfarin therapy. Circulation 41, 1692 - 1711 (2003).
28. Parrish RH, Pazdur DE, O'Donnell PJ: Effect of carbamazepine initiation and discontinuation on antithrombotic control in a patient receiving warfarin: case report and review of the literature. Pharmacotherapy 26, 1650-1653 (2006).
29. Beatty SJ, Mehta BH, Rodis JL: Decreased warfarin effect after initiation of high-protein, low-cerbohydrate diets. Ann. Pharmacother. 39, 744-747(2005).
30. Evans W, Reiling MV: Pharmacogenomics translating functional genomics into rational therapeutics, Science 286,487-491 (1999).